Public awareness of heart failure in Europe: first results from SHAPE.

AIMS Appropriate heart failure (HF) care and adequate resourcing require recognition of its clinical, social, and economic importance by the general public besides healthcare authorities and providers. The extent of public awareness in Europe is not known. METHODS AND RESULTS A total of 7958 subjects were randomly selected from nine European countries (minimum 100/group per country). Each completed a 32-question survey on HF covering recognition, impact on health, comparative prevalence and severity, treatment, and costs. Although 86% of respondents had heard of HF, only 3% could correctly identify HF from a description of typical symptoms and signs, 31% correctly identified angina, and 51% identified transient ischaemic attack/stroke. Only 29% thought that HF signs and symptoms indicate a 'severe' condition. Most thought that HF patients should reduce all physical activity and 34% believed HF a normal consequence of ageing. Sixty-seven per cent thought that HF patients live longer than cancer patients. Only 9% believed that HF leads to greater healthcare expenditure than cancer, HIV, or diabetes. Overall, responses were comparable between countries. CONCLUSION In Europe, community awareness of HF is low. Therefore, the general public is unlikely to demand appropriate measures by healthcare authorities and providers. A better understanding of HF could improve its prevention and management. Strategies to educate the public about HF are needed.

[1]  A. Stewart,et al.  Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. , 1989, JAMA.

[2]  A. Cohen-Solal,et al.  Increasing Awareness and Perception of Heart Failure in Europe and Improving Care—Rationale and Design of the SHAPE Study , 2004, Cardiovascular Drugs and Therapy.

[3]  R. Lancashire,et al.  Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study , 2001, The Lancet.

[4]  Simon Stewart,et al.  Epidemiology, aetiology, and prognosis of heart failure , 2000, Heart.

[5]  Lloyd‐Jones,et al.  Lifetime Risk of Developing Congestive Heart Failure , 2003 .

[6]  E. Beck,et al.  Changing trends in mortality and admissions to hospital for elderly patients with congestive heart failure in Montreal. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[7]  M. Davies,et al.  Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. , 2002, European heart journal.

[8]  N. Freemantle,et al.  Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey , 2002, The Lancet.

[9]  J. McMurray,et al.  Trends in hospitalization for heart failure in Scotland 1980-1990. , 1993, European heart journal.

[10]  William H. Rogers,et al.  Functional Status and Well-Being of Patients with Chronic Conditions , 1989 .

[11]  Thomas Lumley,et al.  Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. , 2003, JAMA.

[12]  Simon Capewell,et al.  The current cost of heart failure to the National Health Service in the UK , 2002, European journal of heart failure.

[13]  N. Bayley,et al.  Failure , 1890, The Hospital.

[14]  H. Liedholm,et al.  Health care costs of heart failure: results from a randomised study of patient education , 2000, European journal of heart failure.

[15]  O. Faergeman,et al.  The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. , 1997, Journal of cardiac failure.

[16]  References , 1971 .

[17]  D E Grobbee,et al.  The epidemiology of heart failure. , 1997, European heart journal.

[18]  B. Psaty,et al.  Health Outcomes Associated with Antihypertensive Therapies Used as First-Line Agents: A Systematic Review and Meta-analysis , 1998 .

[19]  J. Polder,et al.  Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study , 1998, BMJ.

[20]  I. Squire,et al.  Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993–2001 , 2003, Heart.

[21]  S Capewell,et al.  More ‘malignant’ than cancer? Five‐year survival following a first admission for heart failure , 2001, European journal of heart failure.

[22]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[23]  M. Bristow,et al.  Economic impact of heart failure in the United States: time for a different approach. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[24]  T. Allan,et al.  European survey of primary care physician perceptions on heart failure diagnosis and management (Euro-HF). , 2000, European heart journal.

[25]  Jane C Khoury,et al.  Trends in community knowledge of the warning signs and risk factors for stroke. , 2003, JAMA.

[26]  J. McMurray,et al.  Trends in hospitalization for heart failure in Scotland, 1990-1996. An epidemic that has reached its peak? , 2001, European heart journal.

[27]  M. Wallander,et al.  Incidence of newly diagnosed heart failure in UK general practice , 2001, European journal of heart failure.

[28]  J. McMurray,et al.  Economics of chronic heart failure , 2001, European journal of heart failure.

[29]  J. Murabito,et al.  Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study , 2002, Circulation.